Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201


Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903835. [Epub ahead of print]


Body Mass Index and Outcomes in Germ-Cell Tumors.

McGregor BA, Miller RE, O'Donnell E, Albiges LK, Sweeney CJ, Markt SC.

Clin Genitourin Cancer. 2019 Apr 25. pii: S1558-7673(19)30138-7. doi: 10.1016/j.clgc.2019.04.012. [Epub ahead of print]


DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo.

Morel KL, Ormsby RJ, Klebe S, Sweeney CJ, Sykes PJ.

Radiat Res. 2019 May 16. doi: 10.1667/RR15404.1. [Epub ahead of print]


Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 Jun;114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11.


What Does Metastasis-Free Survival Actually Mean?

Sweeney CJ, De Abreu Lourenco R, Hamid AA, Buyse M.

J Clin Oncol. 2019 May 3:JCO1802372. doi: 10.1200/JCO.18.02372. [Epub ahead of print] No abstract available.


Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer.

Sweeney CJ.

Eur Urol Focus. 2019 Mar;5(2):111-113. doi: 10.1016/j.euf.2019.03.008. Epub 2019 Mar 18. No abstract available.


Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF; STOPCAP M1 Radiotherapy Collaborators.

Eur Urol. 2019 Jul;76(1):115-124. doi: 10.1016/j.eururo.2019.02.003. Epub 2019 Feb 28.


Chloroplast-selective gene delivery and expression in planta using chitosan-complexed single-walled carbon nanotube carriers.

Kwak SY, Lew TTS, Sweeney CJ, Koman VB, Wong MH, Bohmert-Tatarev K, Snell KD, Seo JS, Chua NH, Strano MS.

Nat Nanotechnol. 2019 May;14(5):447-455. doi: 10.1038/s41565-019-0375-4. Epub 2019 Feb 25.


Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.

AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, Vaughn DJ, Jacobs LA, Meien S, Grgic M, Kastelan Z, Markt SC, Damrauer SM, Rader DJ, Kember RL, Loud JT, Kanetsky PA, Greene MH, Sweeney CJ, Kubisch C, Nathanson KL, Van Allen EM, Stewart DR, Lessel D; Regeneron Genetics Center (RGC) Research Team.

JAMA Oncol. 2019 Jan 24. doi: 10.1001/jamaoncol.2018.6477. [Epub ahead of print]


Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate Cancer Prostatic Dis. 2019 Jan 14. doi: 10.1038/s41391-018-0121-2. [Epub ahead of print]


Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ.

Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.


Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany.

Withington J, Cole AP, Meyer CP, Seisen T, Schmid M, Lipsitz SR, Sweeney CJ, Dasgupta P, Trinh QD.

BJU Int. 2019 Mar;123(3):385-387. doi: 10.1111/bju.14616. Epub 2018 Dec 9. No abstract available.


A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME.

Cancer. 2019 Feb 15;125(4):524-532. doi: 10.1002/cncr.31836. Epub 2018 Nov 14.


Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.


Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.

Clin Genitourin Cancer. 2019 Feb;17(1):32-37. doi: 10.1016/j.clgc.2018.09.022. Epub 2018 Oct 4.


Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era.

Hamid AA, Markt SC, Vicier C, McDermott K, Richardson P, Ho VT, Sweeney CJ.

Clin Genitourin Cancer. 2019 Feb;17(1):58-64.e1. doi: 10.1016/j.clgc.2018.09.009. Epub 2018 Sep 19.


Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?

Sweeney CJ.

Eur Urol. 2018 Oct;74(4):420-421. doi: 10.1016/j.eururo.2018.06.036. Epub 2018 Jul 12. No abstract available.


Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.

Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ.

Clin Exp Metastasis. 2018 Oct;35(7):649-661. doi: 10.1007/s10585-018-9915-9. Epub 2018 Jun 23.


ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.


What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.

Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF.

Ann Oncol. 2018 May 1;29(5):1249-1257. doi: 10.1093/annonc/mdy071.


Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.


Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce.

Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Am J Med. 2018 May;131(5):517-523. doi: 10.1016/j.amjmed.2017.11.039. Epub 2018 Mar 16.


Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ.

J Clin Oncol. 2018 Apr 10;36(11):1088-1095. doi: 10.1200/JCO.2017.75.3335. Epub 2018 Mar 9.


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ.

J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.


Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.


Reply to Y. Zhu et al.

Xie W, Regan MM, Sweeney CJ.

J Clin Oncol. 2018 Feb 10;36(5):515-516. doi: 10.1200/JCO.2017.76.2872. Epub 2017 Dec 21. No abstract available.


Current treatment strategies for advanced prostate cancer.

Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW.

Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20. Review.


Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.

Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, Choueiri TK.

Cancer. 2018 Mar 1;124(5):925-933. doi: 10.1002/cncr.31154. Epub 2017 Dec 19.


Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators.

J Clin Oncol. 2018 Feb 1;36(4):376-382. doi: 10.1200/JCO.2017.75.3921. Epub 2017 Dec 20.


A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC; Prostate Cancer DREAM Challenge Community.

JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.17.00018.


Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.

Wong SE, North SA, Sweeney CJ, Stockler MR, Sridhar SS.

Clin Genitourin Cancer. 2017 Sep 8. pii: S1558-7673(17)30274-4. doi: 10.1016/j.clgc.2017.08.019. [Epub ahead of print]


TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.


Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.


Chemotherapy for oligometastatic prostate cancer.

Dorff TB, Sweeney CJ.

Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446. Review.


Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.


Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.


Prostate cancer: A new standard-of-care for advanced-stage disease.

Hamid AA, Sweeney CJ.

Nat Rev Clin Oncol. 2017 Oct;14(10):592-593. doi: 10.1038/nrclinonc.2017.120. Epub 2017 Aug 8. No abstract available.


The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.

Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW.

Prostate. 2017 May;77(13):1303-1311. doi: 10.1002/pros.23390. Epub 2017 Aug 1.


Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.

Miller RE, Markt SC, O'Donnell E, Bernard B, Albiges LK, Beard C, Sweeney CJ.

Eur Urol Focus. 2017 Dec;3(6):621-628. doi: 10.1016/j.euf.2016.10.005. Epub 2016 Oct 26.


Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists.

Briganti A, De Santis M, Giannarini G, Sweeney CJ.

Eur Urol Focus. 2016 Dec;2(5):463-464. doi: 10.1016/j.euf.2016.11.017. Epub 2016 Dec 13. No abstract available.


Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors.

Howard SA, Rosenthal MH, Qin L, Matalon SA, Bernard BD, Beard CJ, Sweeney CJ.

Am J Clin Oncol. 2018 Oct;41(10):949-952. doi: 10.1097/COC.0000000000000399.


Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL.

Clin Genitourin Cancer. 2017 Oct;15(5):563-569.e3. doi: 10.1016/j.clgc.2016.10.011. Epub 2016 Oct 28.


Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Ann Oncol. 2017 May 1;28(5):1098-1104. doi: 10.1093/annonc/mdx041.


Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo.

Morel KL, Ormsby RJ, Bezak E, Sweeney CJ, Sykes PJ.

Radiat Res. 2017 May;187(5):501-512. doi: 10.1667/RR14710.1. Epub 2017 Mar 3.


"Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.

Murphy DG, Sweeney CJ, Tombal B.

Eur Urol. 2017 Jul;72(1):1-3. doi: 10.1016/j.eururo.2017.02.036. Epub 2017 Mar 7.


Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.


Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.

Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ.

Cancer. 2017 May 1;123(9):1536-1544. doi: 10.1002/cncr.30503. Epub 2017 Jan 5.


Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer.

Clement JM, Sweeney CJ.

J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3. Review.


Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.


National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?

Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL.

Cancer. 2016 Nov 15;122(21):3371-3377. doi: 10.1002/cncr.30205. Epub 2016 Jul 19.

Supplemental Content

Loading ...
Support Center